• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性肌炎和皮肌炎患者血清可溶性肿瘤坏死因子受体水平升高。

Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis.

作者信息

Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T

机构信息

First Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.

出版信息

Clin Rheumatol. 2000;19(5):352-9. doi: 10.1007/s100670070027.

DOI:10.1007/s100670070027
PMID:11055823
Abstract

The aim of the study was, to examine the relationship between serum levels of soluble tumour necrosis factor receptors (sTNF-R) and the gene expression of two types of receptor for TNF (TNF-R), a 55 a receptor (TNF-R1) and a 75 kDa receptor (TNF-R2), bloodin peripheral mononuclear cells (PBMC) from patients with polymyositis and dermatomyositis (PM/DM). Soluble tumour necrosis factor receptor 1 (sTNF-R1) and soluble tumour necrosis factor receptor 2 (sTNF-R2) levels in sera from patients were measured by enzyme-linked immunosorbent assay. Expression of TNF-R1 and TNF-R2 mRNAs in PBMC was analysed by Northern blotting. Serum sTNF-R1 and sTNF-R2 levels were elevated significantly in 25 patients with active-stage PM/DM, compared to those in 18 patients with inactive-stage PM/DM and 32 normal controls. Serum concentrations of sTNF-R1 and sTNF-R2 were correlated with PM/DM disease activity. TNF-R1 gene expression was enhanced in freshly isolated PBMC from patients with active-stage PM/DM. In contrast, TNF-R2 mRNA was expressed constitutively in patients with active-stage PM/DM and in normal controls. The expression of TNF-R1 and TNF-R2 mRNAs in PBMC and elevation of their soluble forms in the sera of patients with active-stage PM/DM suggest increased proteolytic cleavage of cell surface TNF-R from PBMC in patients with active-stage PM/DM, and that sTNF-R may regulate TNF-alpha-mediated muscle fibre damage in PM/DM.

摘要

本研究的目的是检测多发性肌炎和皮肌炎(PM/DM)患者外周血单个核细胞(PBMC)中血清可溶性肿瘤坏死因子受体(sTNF-R)水平与两种肿瘤坏死因子(TNF)受体,即55 kDa受体(TNF-R1)和75 kDa受体(TNF-R2)基因表达之间的关系。采用酶联免疫吸附测定法检测患者血清中可溶性肿瘤坏死因子受体1(sTNF-R1)和可溶性肿瘤坏死因子受体2(sTNF-R2)的水平。通过Northern印迹法分析PBMC中TNF-R1和TNF-R2 mRNA的表达。与18例非活动期PM/DM患者和32例正常对照相比,25例活动期PM/DM患者血清sTNF-R1和sTNF-R2水平显著升高。血清sTNF-R1和sTNF-R2浓度与PM/DM疾病活动度相关。活动期PM/DM患者新鲜分离的PBMC中TNF-R1基因表达增强。相反,活动期PM/DM患者和正常对照中TNF-R2 mRNA呈组成性表达。活动期PM/DM患者PBMC中TNF-R1和TNF-R2 mRNA的表达及其血清中可溶性形式的升高表明,活动期PM/DM患者PBMC中细胞表面TNF-R的蛋白水解切割增加,且sTNF-R可能调节PM/DM中TNF-α介导的肌纤维损伤。

相似文献

1
Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis.多发性肌炎和皮肌炎患者血清可溶性肿瘤坏死因子受体水平升高。
Clin Rheumatol. 2000;19(5):352-9. doi: 10.1007/s100670070027.
2
Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis.多发性肌炎和皮肌炎患者白细胞介素-1受体拮抗剂产生异常。
Intern Med. 2000 Feb;39(2):128-35. doi: 10.2169/internalmedicine.39.128.
3
Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis.成年多发性肌炎/皮肌炎患者血清新蝶呤水平升高。
Br J Rheumatol. 1997 Jun;36(6):656-60. doi: 10.1093/rheumatology/36.6.656.
4
Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response.多发性肌炎/皮肌炎患者血清白细胞介素-1受体拮抗剂水平升高。一种疾病活动的生物学标志物,可能与缺乏急性期蛋白反应有关。
Arthritis Rheum. 1994 Dec;37(12):1744-51. doi: 10.1002/art.1780371206.
5
Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity.多发性肌炎和皮肌炎患者血清白细胞介素 15、白细胞介素 2 受体和肿瘤坏死因子受体浓度:与疾病活动的相关性。
Rheumatol Int. 2012 Mar;32(3):639-43. doi: 10.1007/s00296-010-1692-y. Epub 2010 Dec 4.
6
The TNF-alpha system in heart failure and after heart transplantation: plasma protein levels, mRNA expression, soluble receptors and plasma buffer capacity.心力衰竭及心脏移植后肿瘤坏死因子-α系统:血浆蛋白水平、mRNA表达、可溶性受体及血浆缓冲能力
Eur Heart J. 1999 Jun;20(11):833-40. doi: 10.1053/euhj.1998.1478.
7
Interleukin-35: A Serological Biomarker for Patients with Polymyositis/Dermatomyositis.白细胞介素-35:多发性肌炎/皮肌炎患者的血清学标志物。
J Interferon Cytokine Res. 2019 Nov;39(11):720-725. doi: 10.1089/jir.2019.0063. Epub 2019 Jul 8.
8
Serum tumor necrosis factor-alpha levels and components of the metabolic syndrome in obese adolescents.肥胖青少年的血清肿瘤坏死因子-α水平与代谢综合征的组成成分
Metabolism. 2004 Jul;53(7):863-7. doi: 10.1016/j.metabol.2004.02.007.
9
Early detection of increased tumour necrosis factor alpha (TNFalpha) and soluble TNF receptor protein plasma levels after trauma reveals associations with the clinical course.创伤后早期检测肿瘤坏死因子α(TNFα)和可溶性TNF受体蛋白血浆水平升高,揭示了其与临床病程的关联。
Acta Anaesthesiol Scand. 2001 Mar;45(3):364-70. doi: 10.1034/j.1399-6576.2001.045003364.x.
10
Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.多发性肌炎和皮肌炎患者血清可溶性CD163水平升高:与肌肉组织中的巨噬细胞浸润有关。
J Rheumatol. 2015 Jun;42(6):979-87. doi: 10.3899/jrheum.141307. Epub 2015 Apr 15.

引用本文的文献

1
Comparison of cytokine/chemokine profiles between dermatomyositis and anti-synthetase syndrome.皮肌炎与抗合成酶综合征细胞因子/趋化因子谱的比较。
Front Neurol. 2022 Dec 8;13:1042580. doi: 10.3389/fneur.2022.1042580. eCollection 2022.
2
Epilepsy as a Comorbidity in Polymyositis and Dermatomyositis-A Cross-Sectional Study.多发性肌炎和皮肌炎合并癫痫:一项横断面研究。
Int J Environ Res Public Health. 2021 Apr 10;18(8):3983. doi: 10.3390/ijerph18083983.
3
Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies.
特发性炎性肌病治疗中的新型治疗选择
Curr Treat Options Neurol. 2018 Jul 23;20(9):37. doi: 10.1007/s11940-018-0521-6.
4
A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.英夫利昔单抗治疗难治性多发性肌炎和皮肌炎的随机、双盲、安慰剂对照试验。
Semin Arthritis Rheum. 2018 Jun;47(6):858-864. doi: 10.1016/j.semarthrit.2017.10.010. Epub 2017 Oct 16.
5
Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel.患有冻疮样狼疮和英夫利昔单抗诱导性肌炎的结节病患者:对促肾上腺皮质激素凝胶的反应
Respir Med Case Rep. 2015 Nov 19;17:5-7. doi: 10.1016/j.rmcr.2015.11.001. eCollection 2016.
6
Immunotherapies for Immune-Mediated Myopathies: A Current Perspective.免疫介导性肌病的免疫治疗:当前视角。
Neurotherapeutics. 2016 Jan;13(1):132-46. doi: 10.1007/s13311-015-0394-2.
7
Targeted immunotherapy trials for idiopathic inflammatory myopathies.特发性炎性肌病的靶向免疫治疗试验。
J Neurol. 2013 Feb;260(2):368-85. doi: 10.1007/s00415-012-6590-7. Epub 2012 Jun 30.
8
Tumor necrosis factor α release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients.皮肤狼疮和皮肌炎患者外周血单个核细胞中肿瘤坏死因子α的释放。
Arthritis Res Ther. 2012 Jan 4;14(1):R1. doi: 10.1186/ar3549.
9
Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab.阿达木单抗治疗常规治疗抵抗的皮肌炎相关间质性肺病的成功案例。
Rheumatol Int. 2012 Nov;32(11):3587-90. doi: 10.1007/s00296-011-2220-4. Epub 2011 Nov 17.
10
Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies.肿瘤坏死因子-α作为特发性炎性肌病的潜在治疗靶点。
J Neurol. 2011 Jun;258(6):961-70. doi: 10.1007/s00415-011-5907-2. Epub 2011 Jan 21.